Cyclacel Pharmaceuticals, Inc.
CYCC
$0.3181
-$0.0359-10.14%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -100.00% | 150.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -100.00% | 150.00% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -100.00% | 150.00% | |||
| SG&A Expenses | -23.36% | -23.88% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -16.42% | -40.05% | |||
| Operating Income | 16.03% | 40.26% | |||
| Income Before Tax | 14.26% | 40.94% | |||
| Income Tax Expenses | 668.57% | 49.03% | |||
| Earnings from Continuing Operations | -55.95% | 39.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -55.95% | 39.91% | |||
| EBIT | 16.03% | 40.26% | |||
| EBITDA | 16.04% | 40.25% | |||
| EPS Basic | 63.69% | 49.60% | |||
| Normalized Basic EPS | 80.04% | 50.46% | |||
| EPS Diluted | 63.69% | 49.60% | |||
| Normalized Diluted EPS | 80.04% | 50.46% | |||
| Average Basic Shares Outstanding | 329.44% | 19.22% | |||
| Average Diluted Shares Outstanding | 329.44% | 19.22% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||